Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

Stanford University10 enrolled

Overview

The goal of this study is to evaluate the prognostic capacity of DMI in a trial assessing the efficacy of adding BPM31510, a lipid nano dispersion of CoQ10 to standard treatment of Glioblastoma (GBM).

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Glioma GBM

Interventions

[6,6-²H₂]-GlucoseOTHER

\[6,6-²H₂\]-Glucose is a stable isotope-labeled glucose used as a metabolic tracer. It is administered orally to assess glucose metabolism using Deuterium Metabolic Imaging (DMI).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Any participant that consents to entry into the Phase II BPM31510 parent study (BPM31510IV-11) * Women of childbearing potential must have a negative pregnancy test * Ability to understand and the willingness to provide written informed consent. Exclusion Criteria: * Refuse to have an IV * Allergy to MRI contrasts * Diabetic patients who are taking insulin

Locations (1)

Stanford University

Palo Alto, California, United States

Outcomes

Primary Outcomes

Progression Free Survival (PFS)

Progression-Free Survival (PFS) is defined as the time from the start of treatment until disease progression or death from any cause, whichever occurs first

Time frame: up to 36 months

Overall Survival (OS)

Overall Survival (OS) is defined as the time from randomization until death from any cause.

Time frame: up to 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.